Whalesbook
The Innovation Imperative: AI as a Catalyst
Sun Pharmaceutical Industries Ltd. and Glenmark Pharmaceuticals Ltd. are making substantial moves to harness Artificial Intelligence (AI) in their research and development pipelines. This strategic adoption is not merely about adopting new technology; it represents a fundamental shift towards accelerating the complex and costly process of bringing novel drugs to market. Sun Pharma's Executive Chairman, Dilip Shanghvi, has emphasized the critical need to leverage AI for accelerating drug development, from patient recruitment in clinical trials to faster regulatory submissions, potentially shaving off up to 1.5 years from the process. Similarly, Glenmark Pharma's Chairman, Glenn Saldanha, sees AI as integral to the entire research cycle, particularly in analyzing clinical trial data and expediting regulatory filings in the short term.
The global pharmaceutical industry is already demonstrating a strong commitment to AI, with drugmakers investing billions in AI for drug discovery. Last year (2025), global investments reached $6.93 billion, a figure projected to soar to $16.5 billion by 2034. This burgeoning investment underscores AI's potential to transform R&D productivity. For Glenmark, the recent out-licensing deal valued at $1.9 billion for its blood cancer drug ISB2001 by its subsidiary IGI to AbbVie, including an upfront payment of $700 million, exemplifies the financial rewards of successful innovation. Sun Pharma, with 20% of its ₹52,041 crore revenue in the last fiscal year (FY25) derived from innovative products, is also prioritizing this shift.
The Analytical Deep Dive: Benchmarking and Sector Dynamics
Sun Pharma, India's largest pharmaceutical company, holds a market capitalization of approximately ₹4.09 trillion and a TTM P/E ratio of around 37.44 as of mid-February 2026. The company has been investing significantly in R&D, with ₹782 crore (5.40% of revenue) invested in Q2 FY26. Analysts maintain a 'Buy' consensus for Sun Pharma, with an average price target of ₹1,963.26, suggesting an upside of over 15%. Glenmark Pharmaceuticals, with a market cap of around ₹57,286 crore and a TTM P/E ratio of approximately 53.8, is also actively pursuing innovation. Analysts hold a 'Buy' rating for Glenmark, with an average 12-month price target of ₹2,192.67, indicating a potential upside of around 8%.
Both companies are part of a larger trend in India where approximately 20% of pharmaceutical firms are actively deploying AI, with 2026 marking a transition from experimentation to scaled adoption. Globally, 95% of pharma and biotech companies are investing in AI, with AI spend expected to grow from $4 billion in 2025 to $25 billion by 2030. Competitors like Dr. Reddy's Laboratories have already launched AI-assisted drug discovery platforms like Aurigene.AI, demonstrating a 35% reduction in cycle time for chemical design to synthesis and testing. The AI in drug discovery market itself is projected to grow significantly, from an estimated $6.93 billion in 2025 to $16.52 billion by 2034. AI's application is particularly pronounced in small molecule drug discovery, where it optimizes molecules and shortens development timelines.
⚠️ The Bear Case: Navigating R&D Risks and Financial Realities
Despite the optimistic outlook, significant challenges and risks persist for Sun Pharma and Glenmark in their AI-driven innovation pursuits. The high costs associated with cutting-edge R&D, coupled with the inherent uncertainty of drug development, could strain financial resources. Glenmark, in particular, carries a P/E ratio of approximately 53.8, suggesting a higher valuation expectation from investors that could lead to volatility if growth falters. While Glenmark's debt-to-EBITDA ratio is a low 0.89, indicating strong financial health, the sheer scale of investment required for AI integration and novel drug development remains substantial. Sun Pharma, with a P/E of around 37.44, also operates in a competitive valuation environment.
While AI promises accelerated timelines, regulatory approval processes for novel drugs remain stringent and time-consuming. Furthermore, the competitive landscape is intensifying; as more companies adopt AI, the differentiation provided by the technology might diminish, becoming a standard operating procedure rather than a unique advantage. Concerns also exist regarding the scalability of AI solutions, especially for public health applications, as highlighted by BCG. Sun Pharma faces potential headwinds from US policy changes like proposed CMS pricing models impacting its branded pharmaceuticals business. For Glenmark, the significant resources previously consumed by its US-based subsidiary IGI are a reminder of the financial demands of R&D, even though recent licensing deals provide financial relief. Past performance, such as Sun Pharma Advanced Research Company's long-term negative returns compared to the Sensex, serves as a cautionary tale about R&D investments not always translating to immediate market gains.
The Future Outlook: Expert Projections and Analyst Views
Analysts largely maintain a positive outlook on both companies. Sun Pharma has seen an upgrade to a 'Buy' rating from MarketsMojo, citing strong fundamentals and an improved technical outlook, with an average analyst price target of ₹1,963.26 and a consensus 'Buy' rating from 38 analysts. Glenmark Pharmaceuticals also holds a 'Buy' consensus rating from 12 analysts, with an average 12-month price target of ₹2,192.67. Glenmark's financial trend is assessed as 'positive', with strong recent growth in net sales and profit after tax. The broader market for AI in pharmaceuticals is projected for substantial growth, with the global AI in pharmaceutical market size expected to reach approximately $16.49 billion by 2034, growing at a CAGR of 27% from 2025 to 2034. This robust market growth trajectory suggests that strategic investments in AI by companies like Sun Pharma and Glenmark are well-aligned with future industry demands.